• Cube Labs subsidiary Serescentia signed a binding agreement to acquire 100% of European Nutritional Supplements for a provisional EUR 390,000.
• Closing is expected by December 2026, with 70% payable at completion and 30% due 12 months later.
• The price is subject to adjustment based on ENS's net financial position at closing.
• ENS reported unaudited 2025 revenue of EUR 308,000, EBITDA of EUR 64,000 and net cash of EUR 102,000.
• Serescentia's first acquisition launches its nutraceuticals and longevity consolidation strategy; two further acquisition opportunities have been identified in Italy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cube Labs S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20282-37-2026_TELEBORSA.pdf), on November 10, 2026, and is solely responsible for the information contained therein.